Drug Pricing And The Trump Effect: How To Make A High Profile Hearing Vanish
Without President Trump’s focus on drug pricing, it is hard to imagine that seven top industry executives would have had to face a grilling in the US Senate Finance Committee. But they can also thank Trump’s indiscretions for helping ensure that the hearing was barely even a one-day story.
You may also be interested in...
Industry's top leaders weren't exactly eager to testify on Capitol Hill. Now they might be wondering why they waited so long. Seven pharma leaders avoided missteps during a Senate Finance Committee hearing on drug pricing Feb. 26.
From Vioxx to EpiPen, industry has been called in to testify before Congress on a range of issues. But with seven big pharma leaders having accepted the Senate Finance Committee's invitation Feb. 26, the stage is set for some exceptional political theater.
House Oversight Committee Ranking Member Jim Jordan suggests that Congress may need to re-evaluate the length of pharma patents and FDA exclusivities.